めまい薬の上手な使い方  [in Japanese] The Effective Use of Anti-Vertigo Drugs  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

There are two bases for the effective use of anti-vertigo drugs. One is being clinically well informed of anti-vertigo drugs and the other is grasping the clinical situations in which anti-vertigo drugs should be used. Regarding the former, we must fully understand the effectiveness, safety, suitability and cost of anti-vertigo drugs. That is to say, we must hold evidence of high quality for anti-vertigo drugs. Regarding the latter, we should make practical use of the concept of Personal-drug (P-drug).<BR>In the Cochrane Library (Issue 3, 2003. Oxford), 85 randomized control studies (RCT) of anti-vertigo drugs were found. However, evidence that could be applied immediately to patients under treatment was insufficient. Especially lacking were the following: (1) RCT for specific vertigo diseases or RCT for specific pathophysiologies of vertigo; (2) outcomes described by patients themselves; and (3) RCTs that were performed with the intention to treat analysis.<BR>In the selection of P-drugs, two treatment goals for anti-vertigo drugs have been designed. One is treatment for the relaxation of symptoms (nausea and vomiting) during the acute phase of vertigo. The other is the prevention of the recurrence of vertigo in the chronic stage of the disease. P-drugs selected by the author were introduced and evidence for each P-drug was also investigated. Because there are no perfect anti-verti-go drugs at present, safety should be the first consideration in the selection of P-drugs. In the application of P-drugs, the root cause leading to the patient's vertigo must be strongly considered.

Journal

  • Equilibrium Research

    Equilibrium Research 63(4), 291-300, 2004-08-01

    Japan Society for Equilibrium Research

References:  20

Codes

  • NII Article ID (NAID)
    10016756225
  • NII NACSIS-CAT ID (NCID)
    AN00001485
  • Text Lang
    JPN
  • Article Type
    REV
  • ISSN
    03855716
  • Data Source
    CJP  J-STAGE 
Page Top